The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive ...
GSK resubmitted an NDA for tebipenem pivoxil hydrobromide to the FDA for cUTI treatment, including pyelonephritis. The phase 3 PIVOT-PO trial showed tebipenem HBr's noninferiority to ...
Rahul Aggarwal, MD, shares key takeaways from the PRESTO trial as well as remaining questions in the field. The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a ...
Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...
An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...
In this debut episode of The UroOnc Minute, host Adam Weiner, MD, a urologic oncologist and surgeon-scientist at Cedars-Sinai Medical Center, introduces listeners to a new Urology Times podcast ...
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response rates and prolonged progression-free survival. Arm 4 demonstrated a median ...
Discover innovative approaches to treating premature ejaculation with insights from leading experts in sexual health and urology. At the 2025 Sexual Medicine Society of North America meeting in ...
Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...
Prostate cancer awareness is crucial year-round, emphasizing screening and meaningful conversations about risk and prevention. Screening guidelines vary, focusing on shared decision-making and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback